For which condition is Frusemide primarily indicated?

Frusemide, also known as furosemide, is primarily indicated for the treatment of cardiogenic pulmonary oedema due to its potent diuretic properties. This medication works by inhibiting the reabsorption of sodium and chloride in the ascending loop of Henle in the kidneys, leading to increased urine production. In cases of cardiogenic pulmonary oedema, the heart's ability to pump blood is compromised, resulting in fluid accumulation in the lungs. The administration of Frusemide helps to relieve this fluid overload by promoting diuresis, thereby improving respiratory function and alleviating symptoms.

In contrast, while dehydration and acute kidney injury may necessitate careful management of fluid status, Frusemide is not typically the first-line treatment for these conditions. In the case of dehydration, rehydration with fluids is a priority, and for acute kidney injury, the approach is often focused on addressing the underlying cause rather than initiating diuretics. As for hypoglycemia, it involves low blood sugar levels and is managed primarily with glucose administration, with no role for Frusemide. Therefore, cardiogenic pulmonary oedema is the condition where Frusemide has a well-established and crucial application.